Enanta Pharmaceuticals, Inc.
NASDAQ:ENTABiotechnology
-$0.09 today
- Market cap
- $253.10M
- Beta
- 0.99
- P/E (TTM)
- -4.3
- EPS (TTM)
- -$2.90
Volume 0.85M
Average 0.17M
Returns on capital
Enanta Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-126.5%
avg -24.4%
ROIC
-31.4%
avg -8.4%
ROA
-29.2%
avg -6.7%
Analysis
ROA is currently the strongest return metric at -29.2% versus its period average of -6.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Scott T. Rottinghaus | Chief Medical Officer | USD 863.71K | 52 | 23.79K | 0.10% |
Yat Sun Or | Chief Scientific Officer | USD 814.29K | 74 | 373.04K | 1.61% |
Jay R. Luly | President, Chief Executive Officer & Director | USD 742.27K | 70 | 862.83K | 3.72% |
Nathaniel S. Gardiner | Consultant | USD 672.68K | 72 | 75.69K | 0.33% |
Brendan Luu | Chief Business Officer | USD 622.86K | 51 | 39.90K | 0.17% |
Matthew Kowalsky | Chief Legal Officer & Corporate Secretary | USD 575.65K | 53 | — | — |
Tara Lynn Kieffer | Chief Operating Officer & Chief Product Strategy Officer | USD 496.85K | 48 | 32.20K | 0.14% |
Harry R. Trout | VP of Finance & Interim Principal Financial Officer | — | 57 | — | — |
Jennifer Viera | Executive Director of Investor Relations & Corporate Communications | — | — | — | — |
Kathleen S. Capps | Executive Director of Accounting, Controller & Interim Principal Accounting Officer | — | 41 | 8.38K | 0.04% |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 8, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
9
$183,166.60
Net Transaction Value
−$183,166.60
Net selling
Most Active
Capps Kathleen S.
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Dec 5, 25Dec 5, 2025 | Luly Jay R. Direct | Sell | $67.5K$67,492.89 |
| Dec 5, 25Dec 5, 2025 | Capps Kathleen S. Direct | Sell | $4.6K$4,596.29 |
| Dec 5, 25Dec 5, 2025 | Trout Harry R. III Direct | Sell | $7.7K$7,712.66 |
| Dec 5, 25Dec 5, 2025 | Rottinghaus Scott T. Direct | Sell | $11.4K$11,355.54 |
| Dec 5, 25Dec 5, 2025 | Luu Brendan Direct | Sell | $19.8K$19,836.62 |
| Dec 5, 25Dec 5, 2025 | Kieffer Tara Lynn Direct | Sell | $30K$29,968.38 |
| Dec 5, 25Dec 5, 2025 | Or Yat Sun Direct | Sell | $34K$34,009.70 |
| Dec 2, 25Dec 2, 2025 | Capps Kathleen S. Direct | Sell | $2.9K$2,889.72 |
| Dec 2, 25Dec 2, 2025 | Trout Harry R. III Direct | Sell | $5.3K$5,304.80 |
Summary
Insiders reported 0 buys worth $0.00 and 9 sells worth $183,166.60 over the last 12 months. That adds up to net selling of $183,166.60. Capps Kathleen S. was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -8.8% | +26.4% (6yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -8.8% over three years. Forward estimates point to Revenue at +26.4% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Enanta Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ENTA's management, answered from reported figures.
Who manages ENTA?
Enanta Pharmaceuticals, Inc. (ENTA) lists 10 active executives. The top listed executive is Scott T. Rottinghaus, Chief Medical Officer.
Are ENTA insiders buying or selling?
Recent insider activity shows net buying of $26.86M.
Continue the stock analysis
Jump to another research area for this company.